The future of U.S. pharma will depend on companies diversifying products and services to address global demand, as well as adopting new operating models that boost R&D productivity.
The Global Base Metals industry profile is an essential resource for top-level data and analysis covering the Base Metals industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information. Scope * Contains an executive summary and data on value, volume and/or segmentation* Provides textual analysis of Global Base Metals's recent performance and future prospects* Incorporates in-depth five forces competitive environment analysis and scorecards * Includes a five-year forecast of Global Base Metals* The leading companies are profiled with supporting key financial metrics * Supported by the key macroeconomic and demographic data affecting the market Highlights * Detailed information is included on market size, measured by value and/or volume* Five forces scorecards provide an accessible yet in depth view of the market's competitive landscape * Market shares are covered by manufacturer or brand Why you should buy this report * Spot future trends and developments * Inform your business decisions * Add weight to presentations and marketing materials * Save time carrying out entry-level researchMarket DefinitionThe base metals market covers copper, aluminium, lead, nickel, tin and zinc. Volumes are annual mine production of each metal, with the exception of aluminum, for which annual primary production is used. Volumes are converted to values using annual average LME prices for each metal. In order to give a more rounded picture of the base metals competitive landscape, the leading companies do not include certain major aluminum producers, focusing instead on some smaller companies active in non-aluminum base metal production. All currency conversions in this profile were calculated using a single average 2009 annual exchange rate for each currency. For the purposes of this report, the global market consists of North America, South America, Western Europe, Eastern Europe, and Asia-Pacific.North America consists of Canada, Mexico, and the United States.South America comprises Argentina, Brazil, Chile, Colombia, and Venezuela.Western Europe comprises Belgium, Denmark, France, Germany, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom.Eastern Europe comprises the Czech Republic, Hungary, Poland, Romania, Russia, and Ukraine.Asia-Pacific comprises Australia, China, India, Japan, Singapore, South Korea, and Taiwan.
Chemical compounds, fusions-acquistions dans le secteur de la chimie T2 2012PwC France
L’enquête de PwC regroupe toutes les fusions et acquisitions en cours entre le 1er janvier 2008 et le 30 juin 2012. Les chiffres, les transactions et les données financières ont été prélevées sur Thomson Reuters.
Retrouvez nos publications : http://www.pwc.com/publications
The Global Base Metals industry profile is an essential resource for top-level data and analysis covering the Base Metals industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information. Scope * Contains an executive summary and data on value, volume and/or segmentation* Provides textual analysis of Global Base Metals's recent performance and future prospects* Incorporates in-depth five forces competitive environment analysis and scorecards * Includes a five-year forecast of Global Base Metals* The leading companies are profiled with supporting key financial metrics * Supported by the key macroeconomic and demographic data affecting the market Highlights * Detailed information is included on market size, measured by value and/or volume* Five forces scorecards provide an accessible yet in depth view of the market's competitive landscape * Market shares are covered by manufacturer or brand Why you should buy this report * Spot future trends and developments * Inform your business decisions * Add weight to presentations and marketing materials * Save time carrying out entry-level researchMarket DefinitionThe base metals market covers copper, aluminium, lead, nickel, tin and zinc. Volumes are annual mine production of each metal, with the exception of aluminum, for which annual primary production is used. Volumes are converted to values using annual average LME prices for each metal. In order to give a more rounded picture of the base metals competitive landscape, the leading companies do not include certain major aluminum producers, focusing instead on some smaller companies active in non-aluminum base metal production. All currency conversions in this profile were calculated using a single average 2009 annual exchange rate for each currency. For the purposes of this report, the global market consists of North America, South America, Western Europe, Eastern Europe, and Asia-Pacific.North America consists of Canada, Mexico, and the United States.South America comprises Argentina, Brazil, Chile, Colombia, and Venezuela.Western Europe comprises Belgium, Denmark, France, Germany, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom.Eastern Europe comprises the Czech Republic, Hungary, Poland, Romania, Russia, and Ukraine.Asia-Pacific comprises Australia, China, India, Japan, Singapore, South Korea, and Taiwan.
Chemical compounds, fusions-acquistions dans le secteur de la chimie T2 2012PwC France
L’enquête de PwC regroupe toutes les fusions et acquisitions en cours entre le 1er janvier 2008 et le 30 juin 2012. Les chiffres, les transactions et les données financières ont été prélevées sur Thomson Reuters.
Retrouvez nos publications : http://www.pwc.com/publications
Presented by Dennis R. Chrisbaum
Director, International Trade Finance
Office of International Trade
U.S. Small Business Administration
409 – 3rd Street, S.W.
Washington, D.C. 20416
Tel: 202.205.6885
E-mail: dennis.chrisbaum@sba.gov
Web: www.sba.gov/international
Presentation by Christine M. Todd, CEO of NVAR, at the 5th Annual Appraisal Summit on June 16, 2010. This event took place at the NVAR Herndon Service Center
Financing activity continued to ramp up in April after a slow start to the month. Total financings (month-to-date) jumped to $92.2 million (this week) from $66.3 million (last week) – a significant +40%. As of last week, a total of 12 deals closed, with a $16 million raise by GOOM Radio being a major contributor. A total of four deals greater than $10 million each helped the overall statistics. Social Networking company DigitalTown Inc. (DGTW-OTCBB) was the top price performer for the week, returning 20%, closely followed by Kingsoft Co. Ltd. (3888-EHK) at 17.6%. The9 Ltd. (NCTY-NasdaqGS) had the worst return, dropping 27.6% in the week after news of its losing the license to operate World of Warcraft in China. Of the 34 companies (with stock price greater than $1), 10 companies on our list had price performances greater than +10%. Only one company returned more than
20%.
An introductory revision presentation here which guides business students through the topic of inflation. The measurement and causes of inflation are outlined together with notes on the potential impact of inflation on business.
China pharmaceutical industry research & forecast to 2016 sample reportAMMindpower
The present title on “China Pharmaceutical Industry Research and Forecast to 2016” offer detailed study on drugs market in terms of OTC, Patent and Generic drugs. Also assess industry performance in terms of recent developments, driving forces, regulatory structure, economy environment and political situation.
Presented by Dennis R. Chrisbaum
Director, International Trade Finance
Office of International Trade
U.S. Small Business Administration
409 – 3rd Street, S.W.
Washington, D.C. 20416
Tel: 202.205.6885
E-mail: dennis.chrisbaum@sba.gov
Web: www.sba.gov/international
Presentation by Christine M. Todd, CEO of NVAR, at the 5th Annual Appraisal Summit on June 16, 2010. This event took place at the NVAR Herndon Service Center
Financing activity continued to ramp up in April after a slow start to the month. Total financings (month-to-date) jumped to $92.2 million (this week) from $66.3 million (last week) – a significant +40%. As of last week, a total of 12 deals closed, with a $16 million raise by GOOM Radio being a major contributor. A total of four deals greater than $10 million each helped the overall statistics. Social Networking company DigitalTown Inc. (DGTW-OTCBB) was the top price performer for the week, returning 20%, closely followed by Kingsoft Co. Ltd. (3888-EHK) at 17.6%. The9 Ltd. (NCTY-NasdaqGS) had the worst return, dropping 27.6% in the week after news of its losing the license to operate World of Warcraft in China. Of the 34 companies (with stock price greater than $1), 10 companies on our list had price performances greater than +10%. Only one company returned more than
20%.
An introductory revision presentation here which guides business students through the topic of inflation. The measurement and causes of inflation are outlined together with notes on the potential impact of inflation on business.
China pharmaceutical industry research & forecast to 2016 sample reportAMMindpower
The present title on “China Pharmaceutical Industry Research and Forecast to 2016” offer detailed study on drugs market in terms of OTC, Patent and Generic drugs. Also assess industry performance in terms of recent developments, driving forces, regulatory structure, economy environment and political situation.
Running head WHOLESALE INDUSTRYWHOLESALE INDUSTRY.docxrtodd599
Running head: WHOLESALE INDUSTRYWHOLESALE INDUSTRY
2
Wholesale industry
Edwaurdo King
November 8, 2018
Dr. B. West
Strayer University
Introduction
Wholesale industry is one of the sectors that ensures that goods from the producers reach to the intended consumers either directly or through the retailers. The industry deals in a variety of consumer goods and services (college grad, 2018). The industry is responsible for the transfer of the required products from the manufacturers to the consumers without making any change in the content or outlook of the products.
Industry Goods and Services
The industry deals with goods such as agricultural products, manufactured goods, and capital goods. The wholesalers use the warehouses as their main offices as they contact their clients to inform them of the available products. The role of the industry is to gather the finished products from different sectors for ease of collection by the retailers from their warehouses. The industry reduces the distance between the producers and consumers (college grad, 2018).
Market Structure and Characteristics
The capital requirement for the industry is enormous thus limiting the number of firms and individuals who can operate in the industry. There is stiff competition in the industry caused by the desire of individual firms to increase their sales volume (Fischer, 2018). The high cost of initial capital discourages the new entrant into the market, therefore, helping in maintaining a low number of firms in the market. Other factors such as product promotion, discounts, and bonuses are used to attract customers to give a difference between the companies. The characteristic in the market shows that the industry operates in an oligopoly market structure (Fischer, 2018).
The wholesale industry lack uniformity of the firms. There are different sizes of the firm in the industry because of the various products they sell. The size of the company is determined the amount of money invested and its level of trade in the market. Other firms are enormous while others are relatively small but operate in the same market (Fischer, 2018).
Microeconomic Relationships, Market Outcomes, and/or Trends
The industry has witnessed several changes in sales volume and the employment rate. The increase in sales in the wholesale sector is as a result of their fair prices compared to the prices offered by the retail trade industry. The number of employment opportunities has been in the rise for the past four months because of the expansion of the industry and improvement regarding trade (Wholesale Trade: NAICS 42, 2018). The number of job opportunities had increased from 5.8 billion in July 2018 to 6 billion in October 2018. The industry has an increasing earning rate from 3.3% in 2014 to 4.5% in 2017. The industry continues to attract more investor because of its rate of return on the investments. (Wholesale Trade: NAICS 42, 2018). Most of the firm has invested in technology th.
Agcapita is Canada's only RRSP and TFSA eligible farmland fund and is part of a family of funds with almost $100 million in assets under management. Agcapita believes farmland is a safe investment, that supply is shrinking and that unprecedented demand for "food, feed and fuel" will continue to move crop prices higher over the long-term. Agcapita created the Farmland Investment Partnership to allow investors to add professionally managed farmland to their portfolios. Agcapita publishes a monthly agriculture briefing.
Global Single- use bioreactors Market Growth Statistics Report 2021-2030MayuriJadhav100
According to Business Intelligence Insights “Global Single-use bioreactors Market is expected to grow from USD 3,192.70 million in 2021 to USD 8.50 million by 2030, at a CAGR of 20.70% during the forecast period 2022-2030
The report contains the following four chapters:
Chapter 1: Global Pharmaceutical Market
Chapter 2: Solutions to Challenges
Chapter 3: Global Players
Chapter 4: Overview of Industry Trends
You may follow my blog: biostrategyanalytics.wordpress.com for further posts related to financial and strategic issues in the Pharmaceutical / Biotechnology sector.
For any questions or recommendations do not hesitate to contact me.
Using Adaptive Scrum to Tame Process Reverse Engineering in Data Analytics Pr...Cognizant
Organizations rely on analytics to make intelligent decisions and improve business performance, which sometimes requires reproducing business processes from a legacy application to a digital-native state to reduce the functional, technical and operational debts. Adaptive Scrum can reduce the complexity of the reproduction process iteratively as well as provide transparency in data analytics porojects.
It Takes an Ecosystem: How Technology Companies Deliver Exceptional ExperiencesCognizant
Experience is evolving into a strategy that reaches across technology companies. We offer guidance on the rise of experience and its role in business modernization, with details on how orgnizations can build the ecosystem to support it.
The Work Ahead: Transportation and Logistics Delivering on the Digital-Physic...Cognizant
The T&L industry appears poised to accelerate its long-overdue modernization drive, as the pandemic spurs an increased need for agility and resilience, according to our study.
Enhancing Desirability: Five Considerations for Winning Digital InitiativesCognizant
To be a modern digital business in the post-COVID era, organizations must be fanatical about the experiences they deliver to an increasingly savvy and expectant user community. Getting there requires a mastery of human-design thinking, compelling user interface and interaction design, and a focus on functional and nonfunctional capabilities that drive business differentiation and results.
The Work Ahead in Manufacturing: Fulfilling the Agility MandateCognizant
According to our research, manufacturers are well ahead of other industries in their IoT deployments but need to marshal the investment required to meet today’s intensified demands for business resilience.
The Work Ahead in Higher Education: Repaving the Road for the Employees of To...Cognizant
Higher-ed institutions expect pandemic-driven disruption to continue, especially as hyperconnectivity, analytics and AI drive personalized education models over the lifetime of the learner, according to our recent research.
Engineering the Next-Gen Digital Claims Organisation for Australian General I...Cognizant
In recent years, insurers have invested in technology platforms and process improvements to improve
claims outcomes. Leaders will build on this foundation across the claims landscape, spanning experience,
operations, customer service and the overall supply chain with market-differentiating capabilities to
achieve sustainable results.
Profitability in the Direct-to-Consumer Marketplace: A Playbook for Media and...Cognizant
Amid constant change, industry leaders need an upgraded IT infrastructure capable of adapting to audience expectations while proactively anticipating ever-evolving business requirements.
Green Rush: The Economic Imperative for SustainabilityCognizant
Green business is good business, according to our recent research, whether for companies monetizing tech tools used for sustainability or for those that see the impact of these initiatives on business goals.
Policy Administration Modernization: Four Paths for InsurersCognizant
The pivot to digital is fraught with numerous obstacles but with proper planning and execution, legacy carriers can update their core systems and keep pace with the competition, while proactively addressing customer needs.
The Work Ahead in Utilities: Powering a Sustainable Future with DigitalCognizant
Utilities are starting to adopt digital technologies to eliminate slow processes, elevate customer experience and boost sustainability, according to our recent study.
AI in Media & Entertainment: Starting the Journey to ValueCognizant
Up to now, the global media & entertainment industry (M&E) has been lagging most other sectors in its adoption of artificial intelligence (AI). But our research shows that M&E companies are set to close the gap over the coming three years, as they ramp up their investments in AI and reap rising returns. The first steps? Getting a firm grip on data – the foundation of any successful AI strategy – and balancing technology spend with investments in AI skills.
Operations Workforce Management: A Data-Informed, Digital-First ApproachCognizant
As #WorkFromAnywhere becomes the rule rather than the exception, organizations face an important question: How can they increase their digital quotient to engage and enable a remote operations workforce to work collaboratively to deliver onclient requirements and contractual commitments?
Five Priorities for Quality Engineering When Taking Banking to the CloudCognizant
As banks move to cloud-based banking platforms for lower costs and greater agility, they must seamlessly integrate technologies and workflows while ensuring security, performance and an enhanced user experience. Here are five ways cloud-focused quality assurance helps banks maximize the benefits.
Getting Ahead With AI: How APAC Companies Replicate Success by Remaining FocusedCognizant
Changing market dynamics are propelling Asia-Pacific businesses to take a highly disciplined and focused approach to ensuring that their AI initiatives rapidly scale and quickly generate heightened business impact.
The Work Ahead in Intelligent Automation: Coping with Complexity in a Post-Pa...Cognizant
Intelligent automation continues to be a top driver of the future of work, according to our recent study. To reap the full advantages, businesses need to move from isolated to widespread deployment.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
1. • Cognizant Reports
The Future of Pharma: A U.S. Sector Review
Executive Summary Emphasis on “economic” outcomes: More
Two powerful megatrends — dramatic decelera- attention to the “economic value” of a therapy
tion in U.S. market growth and significant restruc- as a determinant for research funding and
turing of the healthcare system — are at play in commercialization.
the U.S. pharmaceuticals industry. On the one Personalized medicine: Shifting from “block-
hand, market growth in “developed” markets buster drugs” to “personalized health and
(mostly the U.S., Western Europe and Japan) wellness.”
are significantly lagging the “pharmerging” Externalization and collaboration: More reli-
markets (mostly China, India, Brazil and Russia), ance on external partners, academia, industry
exerting enormous margin pressure on global consortia and entrepreneurs for innovation,
pharma companies. On the other hand, the U.S. productivity and global expansion.
healthcare market is fundamentally restructur- Globalization: Rapid expansion to pharmer-
ing how healthcare is cost-effectively developed, ging countries for scientific talent and new
delivered and reimbursed to improve the overall markets.
health of the population. Health IT adoption: Investing in new technolo-
gies to enable innovation and drive efficiencies.
For an industry whose business has sustained
decades of respectable growth and margins, the The future of U.S. pharma will depend on whether
new environment is testing the resilience and companies can overcome structural shifts and
ingenuity of pharma companies across the sector. adopt operating models aligned to new busi-
Some business models lack the adaptability to ness priorities. For example, some companies
survive the imminent end of the “blockbuster are implementing strategies that respond to
drug” era, even while resource constraints and structural shifts by diversifying products and
sluggish innovation hinder the development of services to address global demand, and others
new capabilities needed to thrive in a rapidly are rethinking their operating models by lever-
evolving market. These are indeed disruptive aging externalization as a means to boost R&D
times for the U.S. pharma industry. productivity. Regardless of whether one follows a
single or multi-pronged approach, it is imperative
Succeeding in a shifting global market and evolv- for U.S. pharma companies to develop strategies
ing healthcare landscape will require pharma- in response to these megatrends and take steps
ceutical companies to adopt innovative business to sustain their next phase of growth and com-
models focused on novel strategies, including: petitiveness in the global market.
cognizant reports | october 2011
2. U.S. Market Landscape Today, the U.S. pharmaceutical industry is facing
According to a report by IMS Institute for a challenging business environment and slowing
Healthcare Informatics, the global pharmaceutical growth. This is in stark contrast to the double
market is expected to reach $1.1 trillion by 2015.1 digit growth rates it experienced in the first half of
In absolute terms, this number presents a rosy the decade (see Figure 2). Further, over the next
outlook for the U.S. pharma industry; how- five years the U.S. market is expected to grow
ever, the anticipated growth is mostly driven by only 0% to 3%. Despite the stagnant growth,
spend in pharmerging countries and on generics the U.S. segment will continue to be the single
(see Figure 1). largest market, reaching between $320 billion
and $350 billion in 2015.2
Components of Change in Total Spending
$1,065B-
1,200
29 $1,095B
1,000 150
119 47
$856B -120
800
$ (billions)
600
400
200
0
2010 Brand LOE Generic Pharmerging Other* 2015
Developed Markets
Source: IMS Market Prognosis, April 2011
*Includes "rest of world "+$27B, other developed market growth +$17B, exchange rate change -$15B.
Figure 1
Spending Growth 2001 – 2010
350 20
300
15
250
Spending (in $ billions)
200
% Growth
10
150 300 307
281 286
270
247
219 234
100 195
172 5
50
0 0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Source: IMS Health, National Sales Perspectives, December 2010
Figure 2
cognizant reports 2
3. PPACA Highlights
• Immediate health insurance market reforms • Medicaid expansion
• Increased Medicaid prescription drug rebates • State exchanges established
• Medicare Part D “donut hole” relief begins • Individual mandate and subsidies • Medicare Part D
• Comparative effectiveness institute established • Employer mandate “donut hole“ closed
2010 2011 2013 2014 2018 2020
Coverage expansions take effect
• Fee on drug manufacturers • Increase Medicare payroll tax • 40% excise tax on high-cost
by 0.9% on earned income health plan
• Impose 3.8% tax on
investment income
• Eliminate deduction for
Medicare Part D subsidy
• Excise tax on medical devices
Source: Ernst & Young LLP
Figure 3
With its position of prominence, winning in the a prolonged economic malaise have precipitated
U.S. healthcare market is a priority for global a much steeper decline. Also, the 2010 PPACA
pharma companies. Consequently, the changes to bill gave impetus to a much-needed restructur-
the U.S. healthcare system, triggered by the pass- ing of the healthcare system, setting priorities
ing of the Patient Protection and Affordable Care for a favorable regulatory environment, a focus
Act (PPACA), are a top priority for the pharma on patient-centric healthcare and the use of IT to
industry. While major portions of the legislation enable cost-effective and quality healthcare.
do not take effect until 2014 (see Figure 3),3 the
bill has put in motion several important changes The Looming Patent Cliff
that the industry has already begun to address, The impact of loss of exclusivity (LOE) on
such as coping with imminent price reductions, developed markets is assessed at $120 billion
greater transparency, comparative effectiveness over the next five years, with a single-year plunge
and health IT. of $35 billion in 2013 (i.e., the “patent cliff”).
This “loss” is barely offset by protected brands
Collectively, a bleak outlook for U.S. market and new launches during the same period (see
growth and an inevitable restructuring of the Figure 4, next page). The era of blockbuster drugs
healthcare system are two megatrends that will has ended; current drug pipelines lack the poten-
influence the U.S. pharma industry. tial to generate the sizeable revenue and margins
that the industry once enjoyed. Despite being
Forces Shaping the Pharma Industry among the top industries in R&D investments, the
Underlying the megatrends are fundamental number of new drugs brought to market contin-
forces shaping the future of the pharmaceuti- ues to fall (see sidebar, next page). Further, insti-
cal industry. A slowdown in U.S. pharma spend tutions and patients alike have rapidly switched
was expected, but the combined forces of a to the use of generics to contain the cost of
looming patent cliff, a rapid switch to generics and healthcare.
cognizant reports 3
4. Developed Markets Patent Expiries
$171B
47
31 36 34
23
-14 -18
-26 -26
-35
2011 2012 2013 2014 2015
-$119B
Pre-expiry Spending Total = $171B Lower Brand Spending Total = -$119B
Source: IMS Institute for Healthcare Informatics; MIDAS, December 2010
Notes: Pre-expiry spending are the projected sales in the year prior to expiry. Lower brand spending reflects the expected impact
in that year on drug spending of patent expiries (including continuing impact from expiries in prior years).
Figure 4
Declining R&D Productivity
R&D productivity, key to the growth and success of the industry, has declined dramatically in the last
few years. The cost of developing and bringing a molecule to market is now estimated at $1.3 billion.
However, company revenues are not growing fast enough to sustain such spending levels. The FDA
numbers on new drug applications and approvals illustrate the decline in R&D productivity.
The 23 new molecular entity applications filed in 2010 with the Center for Drug Evaluation and
Research is the lowest number recorded in the last 10 years, if the year 2002 is excluded, when
only 22 were submitted (see Figure 5). R&D spend has also risen considerably, from $47.6 billion in
2005 to $67.4 billion in 2010, while drug approvals stagnated, with only 22 approved on average in
the last five years (see Figure 6, next page). This doesn’t bode well for an industry that spent close
to one-fifth of its revenues4 on R&D in 2010. Many companies relied on mergers and acquisitions
to work themselves out of the R&D crisis. Although this approach built scale and broadened the
product portfolios of many companies, it hasn’t really improved their ability to innovate.
Drug Applications Filed with FDA
40
35
30
25
20
15
10
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
NME applications NME and BLAs approved by FDA
Source: "New Molecular Entity Approvals for 2010," FDA.
* 2004 – 2010 represents applications for new molecular entities (NMEs) filed under new drug applications (NDAs)
and therapeutic biologics filed under original biologic license applications (BLAs).
2001 – 2003 represents NMEs but not therapeutic biologics.
Figure 5
cognizant reports 4
5. U.S. Pharma R&D Productivity
70 38
36
65 34
NMEs and BLAs Approved
32
60 30
$ Billions
28
55 26
24
50 22
20
45 18
2004 2005 2006 2007 2008 2009 2010
R&D Expenditure ($ billions) NME and BLAs approved by FDA
Source: PhRMA and Nature Reviews Drug Discovery
Figure 6
Growth in Generics Market Share
85%
80%
75%
70%
65%
60%
2006 2007 2008 2009 2010
Market Available for Generic Substitution Generic Market Share
Source: IMS Health, National Prescription Audit, December 2010
Figure 7
Preference for Generics And it now takes only six months to replace over
A growing trend that is hurting established 80% of the prescription volume of a drug that
players is the introduction of newer generics to loses its patent (see Figure 8, next page).
substitute for blockbuster drugs that are los-
ing patent protection. Moreover, an increased While the market’s shift to generics puts pressure
drive by payers to switch to lower-cost generics, on margins and revenue in developed markets, it
when available, has created a surge in demand is also an opportunity for future growth in phar-
for these products. The generics market in the merging nations. To capitalize on this growth,
U.S., according to a market report by RNCOS,5 many top U.S. pharmaceuticals companies have
is set to grow at 10% CAGR from 2010 to 2013 entered into alliances or acquired big generic
and reach $108.5 billion over that timeframe. players in developed and emerging markets
Already, generics constituted 78% of all dispensed (see Figure 9, next page).
prescriptions in the U.S. in 2010 (see Figure 7).
cognizant reports 5
6. Brand Prescription Share of Molecule Post-Expiry
100%
% Share of pre-expiry molecule total Rx
75%
50%
25%
0%
-1 0 1 2 3 4 5 6 7 8 9 10 11 12
Months since patent expiry
2006 2007 2008 2009 2010
Source: IMS Health, National Prescription Audit, February 2011
Figure 8
Historical Generic Drugmaker Acquisitions Over $1 Billion
Year Acquisition Acquirer Purchase Price
Target ($ billions)
2010 Ratiopharm Teva 5.0
2009 Arrow Group Watson 1.0
2009 EBEWE Pharma Sandoz 1.3
2008 Barr Teva 7.5
2007 Merck KGaA Mylan 6.7
2007 Mayne Hospira 2.1
2006 Ivax Teva 7.4
2006 Andrix Watson 1.9
2005 Hexal Sandoz 5.3
2005 Eon Labs Sandoz 2.6
2004 Sicor Teva 3.4
Source: Morningstar
Figure 9
Economic Slowdown that patient office visits declined by 4.2% in 2010,
Starting in 2008, the current period has been and the number of patients initiated into new
termed the worst economic climate in the therapy for chronic health conditions decreased
U.S. since the Great Depression. Economic by 3.4 million.7 The report also observed a shift
performance in 2009 was especially dismal, toward Medicaid and Medicare Part D, with
with peak unemployment reaching 10.1%, the increases of 13.7% and 6.4%, respectively.
Consumer Confidence Index dipping to 25.3 in
February and GDP contracting 5% in October.6 Rethinking the Regulatory Framework
The Pharmaceutical Research and Manufactur-
With the deteriorating economic situation in the ers of America (PhRMA) reports that it takes
U.S., more patients have entered the rolls of the between 10 and 15 years — and costs $1.3 billion —
uninsured, requiring many to make trade-offs on to bring a drug to market. Also, the FDA has noted
their healthcare costs, including noncompliance that the number of new drug submissions has
with medication regimens, deferment of care and not kept pace with increasing R&D budgets (see
greater reliance on government subsidized care. Figure 6, previous page). The FDA has attributed
The IMS Institute for Health Informatics reports this decline in R&D productivity to the fact that
cognizant reports 6
7. “the medical product development process is Innovation in Clinical Evaluations & Personalized
no longer able to keep pace with basic scientific Medicine to Improve Product Development and
innovation.” The FDA’s recent “Strategic Plan for Patient Outcomes”), and one relates to the novel
Regulatory Science”8 attempts to apply 21st cen- use of information technology (“Harness Diverse
tury techniques and technology for modernizing Data Through Information Sciences to Improve
the regulatory framework to speed innovation Health Outcomes”). In an industry that is heavily
and improve public health. regulated, any change might be viewed with skep-
ticism, but with a vision of modernization and
Among the eight priority areas identified by the an implementation path involving public-private
FDA, two relate to the pre-clinical and clinical partnership, the FDA’s plan is a much needed step
development of medicines (“Modernize Toxicology in the right direction.
to Enhance Product Safety” and “Stimulate
Legislative Reform
U.S. healthcare reform is centered on the core issues of access, affordability and quality healthcare.
Providing health insurance for the currently uninsured, improving the quality of care delivered and
lowering costs of existing activities will impact pharmaceutical companies, directly and indirectly.
An increasing focus on drug safety, constraints on marketing and continuing healthcare regu-
lations govern every aspect of the drug value chain, from bringing a product to market, to its
eventual use in patient care. In addition, U.S. healthcare reform may fundamentally impact how
a product reaches a patient, at what price and who pays for it. Provisions in the reform require
pharmaceutical companies to offer discounts on branded prescription drugs for Medicare Part D
participants, shrinking the margins on such drugs. It will also significantly add to the number of
patients covered under insurance.
Governments in developed and emerging markets — sensitive to price largely due to the absence of
widespread healthcare insurance and out-of-pocket payments made by uninsured consumers — are
enacting healthcare regulations and reforms to reduce spiraling healthcare costs. Pharmaceutical
companies need to understand the tradeoffs they must make to factor in necessary price cuts with
ways to improve profitability.
Patient-Centric Healthcare records or social media (e.g., PatientsLikeMe).
Traditionally, healthcare has mainly been devel- The information gleaned from this data has the
oped for and delivered to large populations of potential to vastly improve development of new
people with therapies that apply to a shared drugs and identification of adverse events.9
human physiology. However, over the past decade,
scientific and technology advances have opened Health IT
up the possibility of developing diagnostics and Health information technology (HIT) makes
therapies targeted at specific individual traits it possible for healthcare providers to better
(a genetic or risk profile, for example) — in other manage patient care through secure use and
words, personalized for the patient. A patient- sharing of health information.10 Collectively, these
centric approach to healthcare goes beyond technologies — including the use of electronic
developing personalized therapies but includes health/medical records (EHR/EMR), telehealth
the complete involvement of the patient and care- devices, remote monitoring technologies and
givers in the detection, prevention, treatment and mobile health applications — have the poten-
management of the medical condition. tial to improve quality of care, reduce costs and
empower consumers.
This approach necessitates the open and collabor-
ative sharing of medical information, which can be As part of the federal strategic plan for HIT, the
enabled through effective use of information tech- first goal is to achieve adoption and information
nology, for example, through electronic medical exchange through meaningful use of health IT.
cognizant reports 7
8. The widespread adoption and meaningful use of adoption rates (see Figure 10) have improved
EMR is the cornerstone of a successful HIT strat- over the past year, paving the way for more wide-
egy, and one that will make all the subsequent spread use of health IT.
benefits achievable. Despite a slow start, EMR
Percentage of Office-Based Physicians with EMR/EHR
U.S., 2001 – 2009 and preliminary 2010
55
50.7
50 48.3
45 42
Percent of physicians
40
34.8
35
29.2
30
23.9 24.9
25 20.8 21.8
20 18.2 17.3 17.3 16.9
15 11.8
10.5 10.1
10 6.9
4.5
3.1 3.8
5
0
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Any EMR/EHR system Basic system Fully functional system
Source: CDC/NCHS, National Ambulatory Medical Care Survey, 2001 – 2010
Note: 2010 data is based on preliminary estimates.
Figure 10
Future of U.S. Pharma mercialization process. Health economics and
The inevitable transformation across all seg- outcomes research teams have been blessed
ments of the U.S. healthcare industry will recast with additional resources year-on-year. In fact,
the pharma industry landscape. To survive and 67% of pharmaceutical and device companies
grow, companies need to overcome structural report continually increasing budgets; only 7%
shifts and adopt alternate operating models that anticipate fewer resources in coming years.11
emphasize new business priorities. But growing resources means growing respon-
sibilities and challenges.
The issues confronting the industry are signifi- Personalized medicine: This has the potential
cant; however, the winning companies are already to revolutionize the way therapies are discov-
taking steps to overcome the challenges and cap- ered, developed and delivered. The approach
ture new opportunities. Some of the new priori- is no longer confined to research laboratories
ties for the leaders in the industry are: in academia but is now a mainstay in many
Emphasis on “economic” outcomes: Increas- companies in the industry. Roughly 94% of
ingly, payers prefer and demand therapies companies increased their investments in
that improve overall patient outcomes (rep- personalized medicine by 75% in the last five
resented by clinical, economic and health out- years and plan to increase it by another 53%
comes). The economic outcome signifies the in the coming five years, according to a sur-
cost/benefit trade-off of a novel therapy, tak- vey by Tufts Center for Drug Development (see
ing into consideration the total cost of treat- Figure 11, next page). Also, personalized medi-
ment and subsequent disease management. cines make up 12% to 50% of current clinical
Comparative effectiveness supported by credi- pipelines, according to the report. Already,
ble evidence is now a key factor in most pricing a few notable examples, such as Gleevec®/
and reimbursement levels set by government Novartis and Herceptin®/Roche-Genentech,
and private payers. Pharma companies should have shown great success.
develop the capabilities to conduct health Externalization and collaboration: Large
economics studies and outcome research pharma’s significant assets in research and
and incorporate comparative effectiveness sales force have been the industry’s answer to
as an important gating factor in their com- growth in the past decade; however, the end of
cognizant reports 8
9. the blockbuster era requires companies to refo-
Contribution to Global Growth
cus their attention on core capabilities required
100
for future growth. Refocusing on the core helps
companies operate from a position of strength
Contribution to growth (%)
80 30%
and seek external partners and collabora-
46%
tors for complementary strengths, making a 60
whole that’s greater than the sum of the parts.
Whether the partnership is with academia, 40 15%
startups, consortia for new scientific discov- 8%
eries or with functional service providers for 20
32%
24%
cost-efficient, scalable and global operations,
pharma companies view externalization as an 0
2005 – 2009 2009 – 2014
integral part of their growth strategy.
Rest of World EU5
Globalization: Growth in developed markets Tier 1-3 Pharmerging Canada
is on the decline, while pharmerging markets Japan U.S.
are promising solid growth. These markets are Rest of Europe
expected to grow at 15% to 17% in 2011. Over Source: IMS Health Market Prognosis, March 2010
the next five years, spending on medicines Tier 1 = China
Tier 2 = Brazil, Russia, India
in these markets is projected to reach $285 Tier 3 = Venezuela, Poland, Argentina, Turkey, Mexico, Vietnam,
billion to $315 billion, double the $151 billion South Africa, Thailand, Indonesia, Romania, Egypt,
Pakistan, Ukraine
spent in 2010. According to IMS, they are also
Figure 12
expected to contribute 46% of the global mar-
ket growth from 2009 through 2014, up from
30% in 2005 to 2009 (see Figure 12). Health IT adoption: With the goals of improv-
ing quality, affordability and innovation in
A significant portion of the pharmerg- healthcare, the federal government has allot-
ing markets are from generics sales, which ted up to $20 billion to fund the infrastructure
poses a particular challenge for U.S. pharma and programs for health IT. The implementa-
companies that have typically focused on tion of EMR/EHR among patients and provid-
branded drugs for their revenue. As com- ers aims to improve coordination of care and
panies look to expand their reach to global clinical decision-making, reduce medical errors
markets, we expect to see more M&A and increase the sharing of patient outcomes.
activity as a means to acquire local capabilities
and diversification. Also, the secondary use of EMR/EHR data has
the potential to augment and improve clini-
cal development, reduce adverse events and
Increase in Personalized Medicine develop credible evidence for comparative
Research Investment effectiveness. For instance, the Partnership to
80% Advance Clinical Electronic Research consor-
73% tium (PACeR) is investigating ways to utilize
70% EMR data to improve patient selection, proto-
Recent
Increase
col design and modeling. Other technologies
60%
53% such as mobile and cloud platforms are trans-
50% Expected
forming business processes to achieve cost
Increase savings and better outcomes.12
40%
30%
The Road Ahead
With sales nearing $300 billion in a sector known
20% for innovation and exports, the pharma industry
is a major contributor to the U.S. economy. Even
10%
as the industry faces tremendous challenges, the
0%
leading companies will overcome today’s issues
2006–2010 2011–2015 and emerge with their sights set on new oppor-
Source: Tufts Center for the Study of Drug Development, tunities. The progress achieved so far, points to a
November/December 2010 shared optimism for the industry.
Figure 11
cognizant reports 9